modelMiconazole_1
Extends from Pharmacolibrary.Drugs.ATC.G.G01AF04_1.
Information
| name: | Miconazole_1 | |
| ATC code: | G01AF04_1 | route: | oral |
| compartments: | 1 | |
| dosage: | 250 | mg |
| volume of distribution: | 36 | L |
| clearance: | 1.23 | L/h |
| other parameters in model implementation | ||
Miconazole is an imidazole antifungal agent used to treat dermatophytic and yeast infections of the skin, mouth, and vagina. It acts by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes. Miconazole is approved for topical and some mucosal infections and is widely used today.
Pharmacokinetics
Pharmacokinetics reported in healthy adults following single oral administration of miconazole tablets.
References
Simmons, KB, et al., & Merkatz, R (2018). Effects of concurrent vaginal miconazole treatment on the absorption and exposure of Nestorone® (segesterone acetate) and ethinyl estradiol delivered from a contraceptive vaginal ring: a randomized, crossover drug-drug interaction study. Contraception 97(3) 270–276. DOI:10.1016/j.contraception.2017.10.010 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29097225
Lalla, RV, & Bensadoun, RJ (2011). Miconazole mucoadhesive tablet for oropharyngeal candidiasis. Expert review of anti-infective therapy 9(1) 13–17. DOI:10.1586/eri.10.152 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21171872
Hayashi, Y, et al., & Yamada, Y (1995). [Study of serial bronchoalveolar lavage in patients with aspergilloma: cell reaction at the affected sites and penetration of miconazole and flucytosine into the lesion]. Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases 69(5) 517–523. DOI:10.11150/kansenshogakuzasshi1970.69.517 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7602184
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)